In the human genome, miR-451a, miR-144-5p (passenger strand), and miR-144-3p (guide strand) reside in clustered microRNA (miRNA) sequences located within the 17q11.2 region. Low expression of these miRNAs is significantly associated with poor prognosis of patients with renal cell carcinoma (RCC) (miR-451a: P = .00305; miR-144-5p: P = .00128; miR-144-3p: P = 9.45 × 10 −5 ). We previously reported that 
and side-effects remain important issues associated with these treatments. 4 Searching for new therapeutic targets and developing useful prognostic markers are important issues to overcome in new treatments for RCC.
MicroRNAs (miRNAs), which are short, single-strand RNAs (19-22 nucleotides) belong to a group of noncoding RNA molecules that act as pivotal agents responsible for fine-tuning RNA expression in a sequence-dependent manner. 5 A vast number of studies have reported that miRNAs are closely involved in the physiological and pathological processes of disease. 6 In cancer cells, abnormal expression of miRNAs can disrupt regulatory networks and lead to cancer cell development, progression, metastasis, and drug resistance. 5, 7, 8 We have identified antitumor miRNAs (miR-10a-5p, miR-29s, miR-101, miR-149, and miR-451a) and their targets that are involved in the pathogenesis of RCC. [9] [10] [11] [12] [13] This strategy is a novel approach to identify new molecular targets and prognostic markers for RCC.
Previous miRNA biogenesis posits that the passenger strand of miRNA is degraded and does not regulate gene expression. Contrary to this concept, our miRNA expression signature of RCC showed that some miRNA passenger strands are aberrantly expressed in cancer tissues, for example, miR-139-3p, miR-144-5p, miR-145-3p, and miR-150-3p. [14] [15] [16] [17] In fact, we found that some passenger strands actually act as antitumor miRNAs (miR-144-5p, miR-145-3p, miR-149-3p, miR-
150-3p, and miR-199a-3p) through their targeting of oncogenes in
several cancers. 12, [15] [16] [17] [18] [19] These studies suggested the importance of analyzing passenger strands of miRNA duplex in cancer cells.
Our recent study showed that miR-451a was significantly downregulated in RCC tissues and acted as an antitumor miRNA in RCC cells. 13 Interestingly, miR-451a-regulated oncogenic targets were significantly associated with RCC pathogenesis. 13 In the human genome, miR-451a, miR-144-5p (the passenger strand), and miR-144-3p
(the guide strand) are clustered together in chromosomal region 17q11.2. The Cancer Genome Atlas (TCGA) database analyses showed that low expression of miR-144-5p and miR-144-3p was significantly associated with poor prognosis of RCC patients (P = .00128 and P = 9.45 × 10 −5
, respectively). In this study, we focused on miR-144-5p because the functional significance of miRNA passenger strands in RCC pathogenesis is obscure. Here, we studied the antitumor roles of miR-144-5p and identified the oncogenic targets involved in the pathogenesis of RCC. We suggest that identification of novel functions of miRNA passenger strands and the RNA networks they regulate might enhance our understanding of the molecular pathogenesis of RCC.
| MATERIALS AND METHODS

| Clinical RCC specimens and cell lines
We obtained a total of 18 clinical tissue specimens from RCC patients who underwent total nephrectomy at Chiba University Hospital (Chiba, Japan) between 2008 and 2015 ( Table 1 ). All patients in our study provided signed informed consent, and the T3a  a  1  0  eg  1  0  0  0  0  qRT-PCR   12  51  M  G2 > G1  T1b  a  0  0  eg  0  0  0  0  0  qRT-PCR   13  78  M  G2 > G1 > G3  T1b  b  0  0  eg  1  0  0  0  0  qRT-PCR   14  57  M  G1 > G2  T1a  a  0  0  eg  1  0  0  0  0  qRT-PCR   15  54  M  G2 > G1  T3a  a  0  0  eg  0  0  1  0  0  qRT-PCR   16  54  M  G1 > >G3  T2b  a  0  0  eg  1  0  0  0  0  qRT-PCR   17  74  F  G1 > G2  T2a  b  0  0  ig  1  0  0  0  0  qRT-PCR   18  65  M  G1 > G2  T1b  b  0  0  ig  1  0  0  0  0 
| Quantitative RT-PCR
The procedures for PCR quantification were described previously. 11, 20 TaqMan probes and primers for SDC3 (P/N:
Hs01568665_m1; Applied Biosystems) were assay-on-demand gene expression products. Quantitative RT-PCRs (qRT-PCRs) for miR-144-5p (P/N:002148; Applied Biosystems) and miR-144-3p (P/N:002676)
were used to identify the expression levels of miRNAs according to the manufacturer's protocol. To normalize the data for quantification of mRNA and miRNAs, we used human GAPDH (P/N:
Hs02786624_g1; Applied Biosystems), GUSB (P/N: Hs99999908_m1;
Applied Biosystems), and RNU48 (assay ID: 001006; Applied Biosystems).
| Cell proliferation, migration, and invasion assays
Cell proliferation abilities were determined by XTT assays using Cell Proliferation Kit II (Sigma-Aldrich, St. Louis, MO, USA). Cell migration was characterized with wound healing assays. Cell invasion abilities F I G U R E 1 Expression levels, clinical significance, and functional roles of miR-144-5p and miR-144-3p in renal cell carcinoma (RCC). A-C, Expression levels of miR-144-5p and miR-144-3p in RCC clinical specimens. RNU48 was used as an internal control. Spearman's rank test showed a positive correlation between the expression levels of miR-144-5p and miR-144-3p. D,E, From The Cancer Genome Atlas database, patients with low expression levels of either miR-144-5p or miR-144-3p had significantly reduced overall survival. F-H, Cell proliferation was determined by XTT assays. Cell migration activity was determined using migration assays. Cell invasion activity was determined using Matrigel invasion assays. *P < .005; **P < .0001 
| Western blot analysis
Immunoblotting was carried out with monoclonal anti-SDC3 antibodies (1:400 dilution; SAB4301620; Sigma-Aldrich). We used anti-GAPDH antibodies (1:10 000 dilution; ab8245; Abcam, Cambridge, UK) as an internal control. 21 The normalized mRNA expression values in the RNA sequencing data were processed and provided as Z scores. In the present study, patients were divided into two groups:
Z-score ≥ 0 and Z-score < 0.
| Plasmid construction and dual-luciferase reporter assay
The partial wild-type sequence of the SDC3 3′-UTR was inserted between the SgfI-PmeI restriction sites in the 3′-UTR of the hRluc gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). We used sequences that were missing the miR-144-5p target sites (position 2166-2172). The synthesized DNA was cloned into the psiCHECK-2 vector. | 2925
| Immunohistochemistry
Tissue sections were incubated overnight at 4°C with anti-SDC3 antibodies diluted 1:50 (SAB4301620; Sigma-Aldrich).
11,20
| Regulation of targets downstream of SDC3 in RCC
We further investigated pathways regulated by SDC3 in RCC cells.
We analyzed gene expression using si-SDC3-transfected 786-O cells.
Microarray data were used for expression profiling of si-SDC3 transfectants. The microarray data were deposited into GEO (accession no. GSE113066).
| Clinical data analysis based on TCGA datasets
To investigate the clinical significance of miRNAs and genes in RCC,
we used the RNA sequence database in TCGA (https://tcga-data.nci. 
| RESULTS
| Expression levels of miR-144-5p and
miR-144-3p in RCC clinical specimens
As shown in Figure 1 , the expression levels of miR-144-5p and miR-144-3p were significantly lower in cancer tissues compared with those in adjacent noncancerous tissues (P = .0325 and P = .0329, respectively; Figure 1A ,B). Furthermore, Spearman's rank test showed a positive correlation between the expression levels of miR-144-5p and miR-144-3p in clinical specimens (R = 0.891, P < .0001; Figure 1C ). We undertook gain-of-function assays using miRNA transfection into two RCC cell lines. Ectopic expression of miR-144-5p and miR-144-3p showed that both miR-144-5p and miR-144-3p reduced cancer cell proliferation, migration, and invasive abilities in comparison with mock and miR-control transfectants ( Figure 1F -H).
|
| Incorporation of miR-144-5p into the
RNA-induced silencing complex in RCC cells
We 
| Identification of candidate targets of miR-144-5p and miR-144-3p regulation in RCC cells
We searched for candidate targets using a combination of genomewide gene expression and in silico database analyses. The strategy for identification of miR-144-5p and miR-144-3p target genes is shown in Figure S2 . First, we identified 2078 and 1043 genes that had putative target sites for miR-144-5p and miR-144-3p, respectively in their 3′-UTRs based upon the TargetScanHuman 7.1 database. Next, we narrowed down those presumptive targets to 227 and 268 genes, respectively based on expression levels that were upregulated (fold change >1.5) in RCC tissues using the GEO database. Next, we identified 65 and 34 genes that were downregulated after miR-144-5p and miR-144-3p transfection, respectively into RCC cells (Log 2 ratio < −0.5; Tables 2,3) . In this study, we focused on miR-144-5p, the passenger strand of the miR-144 duplex.
As shown in Figure 2 , 65 candidate target genes of miR-144-5p were analyzed, allowing us to construct a heat map. Among those genes, 9 were significantly associated with poor prognosis in RCC patients (P < .001; Figure 3 ). Heat map visualization of those genes is shown in Figure 4A . Patients with high gene signature expression (Z-score ≥ 0) had poorer outcomes (disease-free survival and overall survival) than those with low gene signature expression (Z-score < 0) (P < .0001; Figure 4B ,C). In the present study, we focused on syndecan-3 (SDC3), reportedly related to carcinogenesis in several types of cancers.
| Direct regulation of SDC3 by miR-144-5p in
RCC cells
We asked whether the expression of the SDC3 gene and SDC3 protein decreased in miR-144-5p-transfected RCC cells. As shown in Figure 5A ,B, both mRNA and protein levels were significantly decreased by miR-144-5p transfection compared with the mock, miR-control, or miR-144-3p transfectants.
Next, luciferase reporter assays with a vector that included the 3′-UTR of SDC3 were undertaken to confirm that miR-144-
F I G U R E 2 Heat map showing the expression of 65 genes targeted by miR-144-5p
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| 2927 5p directly regulated SDC3 in a sequence-dependent manner.
The TargetScanHuman database predicted that there was a binding site for miR-144-5p in the 3′-UTR of SDC3 (position 2166-2172; Figure 5C Figure 5D ).
| Effects of silencing SDC3 on cell proliferation, migration, and invasion in RCC cells
We confirmed that the expression levels of SDC3 mRNA and SDC3
protein were decreased by si-SDC3 in RCC cells ( Figure 6A,B) . 
| Expression of SDC3 in RCC clinical specimens
We examined the mRNA expression levels of SDC3 in 17 RCC clinical specimens using qRT-PCR. The mRNA expression levels of SDC3
were significantly upregulated in cancer tissues compared with those in adjacent noncancerous tissues ( Figure 7A ). Spearman's rank test revealed a negative correlation between the expression of SDC3 and miR-144-5p (P = .0409, R = −0.356, Figure 7B ). Next, we investigated the expression levels of SDC3 in RCC clinical specimens by immunostaining. It was found that SDC3 was strongly overexpressed in several cancer lesions compared with that in adjacent noncancerous lesions with the same staining intensity ( Figure 7C ).
| Downstream genes affected by silencing of
SDC3 in RCC cells
Finally, we undertook a genomewide gene expression analysis using si- GAPDH was used as an internal control. *P < .0001. B, Protein expression of syndecan-3 (SDC3) 72 hours after transfection with miR-144-5p or miR-144-3p. GAPDH was used as a loading control. C, miR-144-5p binding sites in the 3′-UTR of SDC3 mRNA. D, Dual-luciferase reporter assays using vectors encoding putative miR-144-5p target sites (positions 2166-2172) in the SDC3 3′-UTR for both wild-type and deletion-type. Normalized data were calculated as the ratio of Renilla/firefly luciferase activities. *P < .005; **P < .001; ***P < .05 (Table 4) , from which a gene expression heat map was constructed (Figure 8A ). In the heat map, we focused on a gene cluster including SDC3
SDC3-treated
(IL18RAP, SDC3, SH2D1A, GZMH, KIF21B, TMC8, GAB3, HLA-DPB2, PLEK, and C1Qb) ( Figure 8B ). Furthermore, patients with high gene signature expression ( Figure 8B , red square) were significantly associated with a lower overall survival rate than those with low gene signature expression ( Figure 8B , blue square) (P = 0.0064, Figure 8C ). Furthermore, high expression of 7 genes (SDC3, PLXDC1, IL18RAP, GZMH, ATP8B3, TBX15, and TMC8) was significantly associated with poor prognosis of RCC patients by TCGA datasets ( Figure S3 ). 
|
Conversely, low expression levels of miR-144-5p and miR-144-3p
were significantly associated with shorter disease-free survival and advanced tumor stage ( Figure S4 ).
The univariate and multivariate Cox proportional hazards model showed that high expression of SDC3 was an independent predictive factor for survival (hazard ratio, 1.77; 95% confidence interval, 1.07-2.97; P = 0.0249), as were well-known clinical prognostic factors such as T stage, M stage, and hemoglobin level (Table 5) .
In further analyses, we investigated the relationships between other genes in the syndecan family (SDC1, SDC2, and SDC4) and RCC pathogenesis. Interestingly, no other SDC family gene had a significant relationship between its expression and patient prognosis, tumor stage, or pathological grade in RCC ( Figure S5 ).
F I G U R E 6
Effects of silencing SDC3 in renal cell carcinoma cell lines. A, SDC3 mRNA expression 72 hours after transfection with 10 nmol/L si-SDC3_1 or si-SDC3_2 into renal cell carcinoma cell lines. GAPDH was used as an internal control. B, Syndecan-3 (SDC3) protein expression 72 hours after transfection with si-SDC3_1 or si-SDC3_2. GAPDH was used as a loading control. C, Cell proliferation was determined with XTT assays 72 hours after transfection with 10 nmol/L si-SDC3_1 or si-SDC3_2. D, Cell migration activity was determined by migration assays. E, Cell invasion activity was determined using Matrigel invasion assays. *P < .0001
| Effect of cotransfection of SDC3/miR-144-5p in 786-O cells
In order to investigate whether the SDC3/miR-144-5p axis is essential for RCC pathogenesis, we applied rescue studies in 786-O cells.
Our present studies showed that cell proliferation, migration, and invasive abilities were recovered by cotransfection of SDC3 expression vector and miR-455-5p mature miRNA compared to miR-144-5p transfection alone (Figure 10 ). These findings suggested that overexpression of SDC3 contributed to aggressiveness of RCC cells.
A schema summarizing these results of the study is shown in Figure S6 .
| DISCUSSION
The general understanding of miRNA biogenesis posits that only guide strands of miRNAs (derived from the miRNA duplex) are incorporated into the RISC and actually modulate target RNA transcripts. 25 Passenger strands of miRNAs are also thought to undergo degradation, becoming nonfunctional. 26 Contrary to this point of view, our miRNA signatures showed that some miRNA passenger strands were aberrantly expressed in several cancer tissues. 15 38 Several studies showed that its expression contributed to angiogenesis. 39, 40 In gastric cancer, aberrant expression of PLXDC1 enhanced cancer cell migration and invasive abilities.
41
TBX15 is a member of the T-box family of transcription factors; dysregulated expression of some TBX members is involved in human disease and carcinogenesis. 42 In thyroid cancer cells, expression of TBX15 induced Bcl2 and Bcl-XL (anti-apoptotic proteins) expression and its overexpression played a role of anti-apoptosis. 43 These studies showed that SDC3 and its regulatory network have potential to be therapeutic targets of RCC. Further analysis of SDC3 could contribute to the development of novel therapeutic strategies for RCC. 44 In conclusion, we showed that the expression of both miR-144-5p and miR-144-3p was significantly downregulated in RCC tissues and that they functioned as tumor suppressors in RCC cells. We found that SDC3 was directly regulated by miR-144-5p and that it is a significant gene in RCC pathogenesis. Overexpression of SDC3 was involved in the pathogenesis of RCC and acted as an oncogene. The antitumor functionality of the passenger strand of miRNA is a new concept in cancer research. Searching for RNA networks controlled by passenger strands of miRNA is a new challenge in studies of RCC pathogenesis.
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